AngioDynamics reported financial results Q2 fiscal 2007 with record net sales of $24.4 million, up 30 percent over the prior year’s second quarter. Excluding the impact of the adoption of SFAS 123R (a standard that accounts for transactions in which companies exchange equity instruments for goods or services), which accounts for stock-based compensation, net income was $2.9 million, an increase of 74 percent over the prior quarter and 38 percent over the prior year.